Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Clinical outcomes of BTKi + Ven treatment in CLL/SLL: double-exposed vs double-refractory patients

Laura Samples • 9 Dec 2023
ASH 2023
Chronic Lymphocytic Leukemia Leukemia Small Lymphocytic Lymphoma BTK inhibitors Venetoclax

Laura Samples, MD, University of Washington, Seattle, WA, shares insights from a study assessing clinical outcomes in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were treated with both covalent BTK inhibitors (BTKi) and venetoclax (Ven). Highlighting the distinction between double-exposed and double-refractory patients, Dr Samples notes poorer overall survival (OS) and progression-free survival (PFS) outcomes in double-refractory patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Laura Samples

2:26
Outcomes of Ven-based regimens in CLL/SLL following intolerance or progression on covalent BTKi's
Laura Samples • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals